IG vs ID Bitter Administration

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

May 7, 2018

Study Completion Date

May 7, 2018

Conditions
Obesity
Interventions
DRUG

Intragastric quinine hydrochloride

A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.

DRUG

Intragastric denatonium benzoate

A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.

DRUG

Intragastric placebo

A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 0.1 ml of water (placebo) per kg body weight was administrated into the stomach.

DRUG

Intraduodenal quinine hydrochloride

A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.

DRUG

Intraduodenal denatonium benzoate

A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.

DRUG

Intraduodenal placebo

A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.

Trial Locations (1)

3000

TARGID, Leuven

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT03985865 - IG vs ID Bitter Administration | Biotech Hunter | Biotech Hunter